CATB - Catabasis Pharmaceuticals, Inc.
| Previous Close | 1.61 |
| Open | 1.63 |
| Bid | 1.60 x 2600 |
| Ask | 1.62 x 500 |
| Day's Range | 1.57 - 1.70 |
| 52 Week Range | 1.09 - 3.78 |
| Volume | 381,299 |
| Avg. Volume | 985,920 |
| Market Cap | 46.166M |
| Beta | 0.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.26 |
| Earnings Date | May 9, 2018 - May 14, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.17 |
- Benzinga•5 hours ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Facebook, Inc. (NASDAQ: FB ) stock traded higher by ...
- Benzinga•8 hours ago
Benzinga's Daily Biotech Pulse: Catabasis Soars On Trial Results, Eloxx Listing, Biomarin Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on April 25) Eleven Biotherapeutics Inc (NASDAQ: EBIO ) Integra Lifesciences ...
- Business Wire•23 hours ago
Catabasis Pharmaceuticals Presents New Edasalonexent Data Showing Significantly Slowed Duchenne Muscular Dystrophy Disease Progression as Measured by MRI Through One Year of Treatment
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, today reported new positive magnetic resonance efficacy results showing slowed disease progression in boys with Duchenne muscular dystrophy (DMD) in the MoveDMD trial through 48 weeks of edasalonexent treatment. Both magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) were performed in the Phase 2 MoveDMD trial and open-label extension. Statistically significant improvement in the rate of change in lower leg composite MRI T2 at 12, 24, 36 and 48 weeks on oral 100 mg/kg of edasalonexent treatment were observed compared to the off-treatment control period (p
- Zacks•yesterday
Catabasis Pharmaceuticals, Inc. (CATB) Sees Hammer Chart Pattern: Time to Buy?
Catabasis Pharmaceuticals, Inc. (CATB) Sees Hammer Chart Pattern: Time to Buy?
- Business Wire•8 days ago
Catabasis Pharmaceuticals to Present Results from the MoveDMD® Trial of Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 70th Annual Meeting
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that it will present new magnetic resonance imaging data from the open-label extension MoveDMD trial of edasalonexent for the treatment of Duchenne muscular dystrophy at the American Academy of Neurology 70th Annual Meeting to be held April 21 – 27, 2018, in Los Angeles, CA, at the Los Angeles Convention Center....
- Zacks•9 days ago
Alnylam (ALNY) Reports Positive Data for RNAi Candidate
Alnylam (ALNY) announced encouraging results from phase I and phase I/II open-label extension studies of givosiran, which is being evaluated for the treatment of acute hepatic porphyrias.
- Zacks•9 days ago
Alkermes Rallies as FDA Accepts NDA for Depression Drug
Shares of Alkermes (ALKS) rose when the FDA accepted for review the new drug application for its depression candidate ALKS 5461 two weeks after it had issued a Refusal to File letter.
- Business Wire•9 days ago
Catabasis Pharmaceuticals Aligns Resources to Focus on Lead Program Edasalonexent for the Treatment of Duchenne Muscular Dystrophy
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced a restructuring of the organization to focus resources on the Company’s late-stage lead program, edasalonexent for the treatment of Duchenne muscular dystrophy .
- Zacks•13 days ago
Here's Why Geron Stock Surged More Than 90% in 6 Months
Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies. The candidate is progressing well in the Janssen sponsored studies.
- Zacks•14 days ago
FDA Lifts Clinical Hold on Bellicum's (BLCM) T Cell Therapy
Bellicum (BLCM) agrees to make amendments to the protocols relating to clinical studies evaluating its T Cell Therapy, BPX-501.
- Zacks•15 days ago
Epizyme (EPZM) Publishes Tazemetostat Phase I Data, Stock Up
Epizyme (EPZM) publishes tazemetostat phase I clinical data in The Lancet Oncology. The study demonstrated favorable safety findings and anti-tumor activity.
- Zacks•15 days ago
Spectrum Pharma Stock Up on Positive Lung Cancer Study Data
Spectrum Pharmaceuticals' (SPPI) poziotinib shows encouraging results in preliminary analysis of data from phase II lung cancer study.
- ACCESSWIRE•last month
Wired News – FDA Permitted a Single Registration Trial Assessing Eiger BioPharma’s Lonafarnib in HDV to Support NDA Filing
Stock Monitor: Catabasis Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 23, 2018 / Active-Investors.com has just released a free research report on Eiger BioPharma, Inc. (NASDAQ: EIGR ) ...
- Thomson Reuters StreetEvents•last month
Edited Transcript of CATB earnings conference call or presentation 15-Mar-18 8:30pm GMT
Q4 2017 Catabasis Pharmaceuticals Inc Earnings Call
- Associated Press•last month
Catabasis Pharmaceuticals posts 4Q loss
The Cambridge, Massachusetts-based company said it had a loss of 24 cents per share. The biopharmaceutical company posted revenue of $250,000 in the period. For the year, the company reported that its ...
- Business Wire•last month
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Reviews Business Progress
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2017, and reviewed recent business progress.
- ACCESSWIRE•last month
Catabasis Pharmaceuticals Inc to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 15, 2018 / Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 15, 2018, at 4:30 PM Eastern ...
- PR Newswire•2 months ago
Catella Strengthens UK Presence by Signing a Conditioned Share Purchase Agreement to Acquire Majority Stake in APAM Ltd
SOLNA, Sweden, March 11, 2018 /PRNewswire/ -- Catella AB has, through Catella Property Fund Management AB ("CPFM"), signed a share purchase agreement to acquire a majority stake in the leading UK real estate investment and asset management company, APAM Ltd. Closing of the transaction requires regulatory approval and other conditions to be fulfilled. APAM Ltd ("APAM") has experienced fast growth over recent years and had revenues of approximately GBP 7 million during the calendar year 2017.
- Business Wire•2 months ago
Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Recent Corporate Developments on Thursday, March 15
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, will report fourth quarter and full year 2017 financial results after the NASDAQ Global Market close on Thursday, March 15, 2018.
- GlobeNewswire•2 months ago
Detailed Research: Economic Perspectives on RPC, Catabasis Pharmaceuticals, Zayo Group, Catalent, ARRIS International, and McCormick & Company — What Drives Growth in Today's Competitive Landscape
NEW YORK, March 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- ACCESSWIRE•2 months ago
Today’s Research Reports on Trending Tickers: Catabasis Pharmaceuticals and Synergy Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / March 2, 2018 / Markets continued to slide Thursday after President Trump announced that tariffs on steel and aluminum imports were on the way. The Dow Jones Industrial Average ...
- ACCESSWIRE•2 months ago
Today’s Research Reports on Trending Tickers: Catabasis Pharmaceuticals and ImmunoCellular Therapeutics
NEW YORK, NY / ACCESSWIRE / February 14, 2018 / Strong performances from banking and technology stocks helped lift the markets further into the green on Tuesday. The Dow Jones Industrial Average gained ...
- Business Wire•2 months ago
Catabasis Pharmaceuticals Reports Edasalonexent Preserved Muscle Function and Substantially Slowed Duchenne Muscular Dystrophy Disease Progression Through More Than One Year of Treatment
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today reported new positive efficacy and safety results showing preservation of muscle function and sustained disease-modifying effects in boys with Duchene muscular dystrophy in the MoveDMD trial open-label extension following 48 and 60 weeks of treatment with edasalonexent.
- Zacks•4 months ago
Amgen Announces Acceptance of MAA for Evenity in Europe
Amgen's (AMGN) regulatory application seeking approval for Evenity as a treatment of osteoporosis gets EMA's acceptance.
